Literature DB >> 12625034

Sumanirole Pharmacia.

Tomas de Paulis1.   

Abstract

Sumanirole is a dopamine D2 agonist under development by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of Parkinson's disease. The compound is currently undergoing phase II trials in Japan and phase III clinical trials in the US.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12625034

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats.

Authors:  Martin Weber; Wei-Li Chang; Michelle R Breier; Alex Yang; Mark J Millan; Neal R Swerdlow
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-25       Impact factor: 4.600

2.  Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism.

Authors:  Alessandro Bonifazi; Hideaki Yano; Michael P Ellenberger; Ludovic Muller; Vivek Kumar; Mu-Fa Zou; Ning Sheng Cai; Adrian M Guerrero; Amina S Woods; Lei Shi; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-03-16       Impact factor: 7.446

3.  Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.

Authors:  Mu-Fa Zou; Thomas M Keck; Vivek Kumar; Prashant Donthamsetti; Mayako Michino; Caitlin Burzynski; Catherine Schweppe; Alessandro Bonifazi; R Benjamin Free; David R Sibley; Aaron Janowsky; Lei Shi; Jonathan A Javitch; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-04-01       Impact factor: 7.446
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.